Tryptamine Therapeutics (ASX:TYP) has received approval from the Swinburne University Human Research Ethics Committee to initiate a world-first clinical trial of TRP-8803 for adult patients with Binge Eating Disorder.
Tryptamine Therapeutics secures human ethics approval for Binge Eating Disorder trial
June 23, 2025 Australian Biotech
Latest Video
New Stories
-
Is this disconnect so entrenched we can no longer recognise the presence of a problem?
November 19, 2025 - - Latest News -
Minister managing the 'double-whammy' of participant and plan growth
November 19, 2025 - - Latest News -
Tryp advances psilocin trial for binge eating disorder as second patient enrolled
November 18, 2025 - - Australian Biotech -
Nyrada advances toward Phase 2a trial of cardioprotective candidate
November 18, 2025 - - Australian Biotech -
We know they're planning something on these issues, because they told us
November 18, 2025 - - Latest News -
The need to honour a strong history while ensuring the future is guided by the 'good guys'
November 17, 2025 - - Latest News -
BMS Australia team cycles across Japan, raising nearly $20,000 for Bowel Cancer Australia
November 17, 2025 - - Latest News